Interní Med. 2019; 21(5): 292-294

Tofacitinib

Mgr. Šárka Sperottová1,2, MUDr. Petra Matalová, Ph.D.1
1 Ústav farmakologie LF UP a FN Olomouc
2 Lékárna FN Olomouc

Tofacitinib (Xeljanz®), is a small molecule that inhibits Janus kinases. They are responsible for signal transduction for activation of
pro-inflammatory – cytokine receptors. Tofacitinib binds ATP and prevents autoactivation of Janus kinases. It is used in the treatment
of chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis or Crohn‘s disease. However, it is also effective against
other inflammatory diseases, such as juvenile idiopathic arthritis. The recommended dosage of tofacitinib is 5 mg twice daily, or 10 mg
twice daily. However, with a higher dose regimen, side effects such as serious infections or herpes zoster are more common.

Keywords: tofacitinib, mechanism of action, indication, dosage

Published: December 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sperottová Š, Matalová P. Tofacitinib. Interní Med. 2019;21(5):292-294.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article


    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.